FOXP3 and cancer: Chemotherapeutic drugs can stimulate tumor-infiltrating lymphocytes and inhibit immunosuppressive cells (24, 25), while PD-1/PD-L1 interaction promotes differentiation of CD4+ T cells into FoxP3+ Tregs (26, 27), inhibits tumor-specific T-cell activities, and induces T-cell apoptosis (28), further suppressing the immune system and resulting in peripheral immune tolerance in cancer patients.